Acute HIV infections during new long-acting prevention options
ACTION: Study of ACuTe Infections On Novel HIV Prevention Modalities
This project looks at when and why people get early (acute) HIV infections while using new long-acting prevention methods like the dapivirine vaginal ring and injectable cabotegravir.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11093469 on NIH RePORTER |
What this research studies
You would be part of work that follows people using long-acting HIV prevention to catch infections early and find out why they happened. Participants undergo regular HIV testing, measurements of drug levels, and resistance testing if infection is found. The team combines clinic data, lab results, and modeling to estimate how often acute infections occur and how resistance could affect future HIV treatment. Results are intended to help clinicians and patients choose and use prevention options more safely.
Who could benefit from this research
Good fit: Ideal candidates are people at substantial risk for HIV who are using or considering long-acting PrEP such as the dapivirine ring or injectable cabotegravir, or who have had recent possible exposures.
Not a fit: People already living with well-controlled HIV on antiretroviral therapy or those not at risk for HIV exposure are unlikely to get direct benefit from participation.
Why it matters
Potential benefit: If successful, the project could reduce missed early infections, guide safer use of long-acting prevention, and limit spread of drug-resistant HIV.
How similar studies have performed: Previous trials showed that dapivirine and injectable cabotegravir can prevent HIV but also recorded some early infections and cases of drug resistance, so this work builds on those findings.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Koss, Catherine Anne Stimets — University of California, San Francisco
- Study coordinator: Koss, Catherine Anne Stimets
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.